Media Centre

Featured Media Release
 

09 May 2014 - GSK discloses 2013 payments to Australian healthcare professionals

As part of our ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid to Australian healthcare professionals (HCPs) and health-related organisations (HCOs) for all sponsorships, grants, speaking engagements and consulting services during the calendar year of 2013.

 
 

Media Releases


GSK completes major three-part transaction with Novartis

Completion of this transaction represents a major step forward in the Group’s strategy to create a stronger and more balanced set of businesses across Pharmaceuticals, Consumer Healthcare and Vaccines.

03/03/2015

 

Sun Pharma to buy GSK’s Opiates business in Australia

GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries Ltd. today announced that their respective wholly owned subsidiaries have reached an agreement related to GSK’s Opiates business in Australia.

03/03/2015

 

Supply update: Zovirax Ophthalmic Ointment (aciclovir 3%)

Regrettably, Zovirax Ophthalmic Ointment (aciclovir 3%) continues to be impacted by a global supply constraint and is unlikely to be available in Australia prior to September 2015.

18/02/2015

 

GSK statement on affordability of vaccines in developing countries

Around 80% of all of GSK’s vaccines, including our pneumococcal vaccine, are provided to developing countries at a substantial discount to western prices. GSK offers the lowest prices to Gavi and UNICEF which can be as little as a tenth of developed...

20/01/2015

 

ADELAIDE HILLS BUSHFIRES: Donation of asthma medication

GSK has responded to the South Australian bushfire emergency by providing eight pharmacies in the Adelaide Hills fire affected areas with a donation of asthma rescue medicine.

08/01/2015

 

Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed via the Australian Pharmaceutical Benefits Scheme (PBS) as a long-term once-daily, maintenance...

01/12/2014

 

Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD

Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand with GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) announcing the listing of Breo Ellipta on the...

01/12/2014

 

Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator treatment to relieve symptoms in...

01/12/2014

 

GSK leads Access to Medicines Index 2014

The Access to Medicines Index published today has ranked GSK top for the fourth consecutive time.

17/11/2014

 

GSK announces multi-million dollar investment in next generation manufacturing

GSK Australia has announced today it will be investing AUD$31 million in next generation manufacturing technology to expand its Boronia site in the outer eastern suburbs of Melbourne.

14/11/2014

1 2 3 4 5 6 7 8 9 10 11 >